Genexis Biotech secures Rs 4 Crore in seed round led by GVFL

Bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. 

The funds will be used to expand bioreactor capacity, set up downstream processing infrastructure, launch new recombinant proteins and enzymes, and boost compliance, sales and distribution capabilities.

Read also- AK Food & Beverages: How a Mother-Son Duo is Bringing Transparency to Meat & Poultry

“Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey, said, Mihir Joshi, Managing Director of GVFL.

Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food and bio-industrial sectors.”

Over the past year, Genexis has expanded its portfolio to include recombinant growth factors, peptidases, and cell culture reagents. The company has forged strategic partnerships with pharmaceutical firms, biotech startups and research labs. Its certified Class 10,000 manufacturing facility is now operational with a GMP-compliant unit in the pipeline.

In its next growth phase, Genexis Biotech plans to enter the regulated biotech export market and forge strategic collaborations with CDMOs, academic institutions and biopharma companies. It also aims to develop encapsulated growth factor formulations for the cosmetics industry.

Advertisment

About Genexis Biotech

Vadodara-based Genexis Biotech was founded in 2019, it is a cutting-edge bio-manufacturing company producing high-quality, animal-free proteins through recombinant technology and precision fermentation. 

Backed by strong in-house R&D and ISO-compliant facilities, it caters to industries such as biopharma, regenerative medicine, cell culture media, and cultivated meat. Genexis is committed to making biomolecules more accessible, ethical, and scalable—driving a greener, self-sufficient biotech future.